← Back to Search

Radiation

Targeted Radiotherapy for Prostate Cancer

N/A
Recruiting
Led By Danny Vesprini, M.D.
Research Sponsored by Sunnybrook Health Sciences Centre
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Tumour nodule visible on MRI occupying <50% of prostate on any axial slice and <50% prostate volume
MRI-visible tumour(s) of PIRADS v2 grade 3 or higher on T2 and diffusion-weighted imaging and/or dynamic contrast-enhanced imaging (multiparametric MRI or mpMRI) with concordant pathology
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 4 years
Awards & highlights
No Placebo-Only Group

Summary

This trial is looking at a new treatment for men with prostate cancer. The treatment involves giving a targeted dose of radiation to the prostate. The goal of the trial is to develop a protocol for this treatment

Who is the study for?
Men aged 18 or older with intermediate risk localized prostate cancer, Gleason score between 3+3 and 4+3, MRI stage T2 or less. They must have a visible tumor on MRI that's less than half the size of the prostate and PSA <20 ng/ml. Short-term hormone therapy is allowed.
What is being tested?
The trial tests a new way to give radiotherapy for prostate cancer using an MR Linac machine. It aims to tailor the radiation dose specifically to each patient's tumor, potentially reducing side effects by either increasing or decreasing the dose as needed.
What are the potential side effects?
Potential side effects include acute and late urinary (GU) and gastrointestinal (GI) toxicity which can affect bladder and bowel function respectively, as well as possible impacts on sexual quality of life.

Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below
Select...
My prostate tumor is visible on MRI and occupies less than half of my prostate.
Select...
My MRI shows a tumor with a grade 3 or higher rating.
Select...
My cancer is at an early stage, not beyond T2 according to MRI results.
Select...
I am a man aged 18 years or older.
Select...
My prostate cancer has a Gleason score of 3+3, 3+4, or 4+3.
Select...
My prostate cancer diagnosis was confirmed with a biopsy and needs intensive radiation treatment.
Select...
I can take care of myself and perform light activities.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~4 years
This trial's timeline: 3 weeks for screening, Varies for treatment, and 4 years for reporting.

Treatment Details

Study Objectives

Study objectives can provide a clearer picture of what you can expect from a treatment.
Primary study objectives
Technical Feasibility
Secondary study objectives
Acute and Late Toxicities

Awards & Highlights

No Placebo-Only Group
All patients enrolled in this study will receive some form of active treatment.

Trial Design

1Treatment groups
Experimental Treatment
Group I: InterventionalExperimental Treatment1 Intervention
All radiotherapy will be delivered on the MR-linac

Find a Location

Who is running the clinical trial?

Sunnybrook Health Sciences CentreLead Sponsor
674 Previous Clinical Trials
1,565,835 Total Patients Enrolled
31 Trials studying Prostate Cancer
12,061 Patients Enrolled for Prostate Cancer
Danny Vesprini, M.D.Principal InvestigatorSunnybrook Health Sciences Centre
~13 spots leftby Dec 2026